Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Future Microbiol. 2010 Feb;5(2):221-39. doi: 10.2217/fmb.09.110.

Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

Author information

  • 1Vaccine Discovery, La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA. mmoutaftsi@idri.org

Abstract

Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.

PMID:
20143946
[PubMed - indexed for MEDLINE]
PMCID:
PMC3363998
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk